CELLINK Q5 2020 Results and MatTek Acquisition
CELLINK
LIFE SCIENCES
The transaction in brief
Enterprise Value on cash- and debt-free basis of $68 million (20% in shares and remaining in cash).
MatTek's revenue reached $16.6 million in 2020, with and EBITDA margin of 21.9 per cent. Pro-forma revenue
growth is expected for 2021 and MatTek's historical growth rate has been in the range of 10 per cent.
MatTek will continue as a part of CELLINK's business area Bioprinting. MatTek will remain under current entity
and management post-transaction.
The Acquisition's completion and the transfer of MatTek's shares are expected to take place by March 24, 2021
provided that all conditions for completion are met. MatTek will be consolidated in CELLINK's financial
statements from second quarter 2021 and in the financial reporting from April 1, 2021.View entire presentation